Response to: Comment on ‘Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines’

TY - JOUR

T1 - Response to

T2 - Comment on ‘Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines’

AU - the European Dermatology Forum (EDF)

AU - the European Association of Dermato-Oncology (EADO)

AU - the European Organization for Research and Treatment of Cancer (EORTC)

AU - Peris, Ketty

AU - Fargnoli, Maria C.

AU - Garbe, Claus

AU - Kaufmann, Roland

AU - Bastholt, Lars

AU - Seguin, Nicole B.

AU - Bataille, Veronique

AU - del Marmol, Veronique

AU - Dummer, Reinhard

AU - Harwood, Catherine A.

AU - Hauschild, Axel

AU - Höller, Christoph

AU - Haedersdal, Merete

AU - Malvehy, Josep

AU - Middleton, Mark R.

AU - Morton, Colin A.

AU - Nagore, Eduardo

AU - Stratigos, Alexander J.

AU - Szeimies, Rolf Markus

AU - Tagliaferri, Luca

AU - Trakatelli, Myrto

AU - Zalaudek, Iris

AU - Eggermont, Alexander

AU - Grob, Jean J.

N1 - Funding Information: K.P. reports receiving grants and personal fees from Almirall and Abbvie, during the conduct of the study, and personal fees from Biogen, Lilly, Celgene, Galderma, LEO Pharma, Novartis, Pierre Fabre, Sanofi, Sandoz, Sun Pharma and Janssen, outside the submitted work. M.C.F. reports receiving personal fees from Roche and Mylan; grants and personal fees from Galderma, during the conduct of the study; grants and personal fees from Abbvie, Almirall, Leo Pharma, Novartis, Sanofi and UCB and personal fees from Janssen and Lilly, Celgene and Pierre Fabre, outside the submitted work. C.G. reports receiving grants and personal fees from Roche; personal fees from Sun Pharma, during the conduct of the study; personal fees from Amgen, MSD, Philogen and Sanofi and grants and personal fees from BMS, Novartis and Neracare, outside the submitted work. R.K. reports receiving personal fees and clinical trial grants from Roche related to aspects of the submitted work, personal fees from Amgen, BMS, Novartis, Regeneron and Actelis, as well as clinical trial grants to his institution from Amgen, BMS, Novartis, Abbvie, Almirall, Biogen, MSD and Pfizer, outside the submitted work. L.B. reports receiving personal fees from Amgen, BMS, Novartis, Merck, Roche, Eisai, Astra Zeneca and Pfizer, outside the submitted work. N.B.-S. reports receiving grants and personal fees from Roche; personal fees from Sun Pharma; non-financial support and other fees from Pelle pharm, during the conduct of the study, and personal fees from Pierre Fabre and Laboratoire Léo, outside the submitted work. V.B. reports giving a few lectures on cutaneous side-effects of targeted therapy and immunotherapy in stage III and IV melanoma for Novartis and MSD.V.d.M. reports receiving fees from Sanofi, Merck and Abbvie and reports receiving payment from BMS to the Hopital Erasme where she was an employee. She also reports receiving research grant from Abbvie and Janssen. R.D. reports having intermittent, project focused consulting and/or advisory relationships with Novartis, Merck Sharp & Dhome (MSD), Bristol-Myers Squibb (BMS), Roche, Amgen, Takeda, Pierre Fabre, Sun Pharma and Sanofi, outside the submitted work. C.H. reports receiving other fees from Pellepharm, during the conduct of the study; personal fees from Sanofi; non-financial support from MEDA; other fees from Novartis and Galderma and grants from Almirall, CERIES/Chanel and Leo, outside the submitted work. A.H. reports receiving grants and personal fees from Amgen, BMS, MerckSerono, MSD/Merck, Novartis Pharma Philogen, Pierre Fabre, Provectus, Regeneron, Roche and Sanofi-Genzyme and personal fees from OncoSec and Sun Pharma, outside the submitted work. C.H. reports receiving personal fees from Amgen, BMS, MSD, Novartis, Sanofi, Incyte, Pierre Fabre and Roche, outside the submitted work. M.H. reports receiving non-financial support from Cynosure Hologic and Perfaction Technologies; grants from Leo Pharma, Procter and Gamble and Sebacia and grants and non-financial support from Lutronic Novoxel, outside the submitted work. J.M. reports receiving grants and personal fees from Roche; personal fees from Sun Pharma, during the conduct of the study; personal fees and grants from Amgen, Almirall, BMS and Novartis and personal fees from MSD, outside the submitted work. M.R.M. reports receiving personal fees from Amgen and BiolineRx; grants and personal fees from Roche and GSK; grants from Astrazeneca; personal fees and other fees from Novartis, Eisai, Array Biopharma,Rigontec and BMS; other fees from Millenium, Pfizer, Regeneron, TCBiopharma, Replimune and Vertex and personal fees, non-financial support and other fees from Immunocore and Merck, outside the submitted work. C.A.M. reports receiving personal fees from Biofrontera and Galderma, outside the submitted work, and reports serving as a board member of Euro-PDT and a national PI for a study sponsored by Biofrontera. E.N. reports receiving personal fees from Novartis, outside the submitted work. A.J.S. reports receiving personal fees and/or research support from Novartis, Roche, BMS, Merck, Abbvie, Pfizer, Sanofi, Regeneron and LEOPharma, outside the submitted work. R.-M.S. reports receiving grants, personal fees and non-financial support from Galderma International and Leo Pharma; grants and non-financial support from Biofrontera, during the conduct of the study; grants and personal fees from Almirall and Novartis; grants from Dr. Wolff-Group, Photonamic, Eli Lilly and Galapagos and personal fees and non-financial support from Janssen, outside the submitted work. L.T. reports no conflict of interest. In addition, L.T reports having a pending patent for TIMER applicator. M.T. reports receiving personal fees from Genesis Pharma, Leo Pharma, Janssen Pharma and Novartis, outside the submitted work. I.Z. reports receiving grants and personal fees from Roche Oncology; personal fees from Mylan, during the conduct of the study; personal fees from Sanofi Regeneron; grants from Abbvie and personal fees from MSD, Novartis and Meda Pharma, outside the submitted work. A.E. reports receiving personal fees, all outside the submitted work, from BMS, Ellipses, GSK, HalioDX, Incyte, IO Biotech, ISA pharmaceuticals, MedImmune, Merck-Serono, MSD, Novartis, Pfizer, Polynoma, Sellas and Sanofi, as well as equity in RiverDiagnostics, SkylineDx and Theranovir. J.J.G. reports receiving personal fees from MSD, BMS, Roche, Novartis, Amgen, Pierre Fabre Sanofi, Merck Pfizer and Sunpharma, outside the submitted work. Funding Information: K.P. reports receiving grants and personal fees from Almirall and Abbvie , during the conduct of the study, and personal fees from Biogen, Lilly, Celgene, Galderma, LEO Pharma, Novartis, Pierre Fabre, Sanofi, Sandoz, Sun Pharma and Janssen, outside the submitted work. M.C.F. reports receiving personal fees from Roche and Mylan; grants and personal fees from Galderma , during the conduct of the study; grants and personal fees from Abbvie , Almirall , Leo Pharma , Novartis , Sanofi and UCB and personal fees from Janssen and Lilly, Celgene and Pierre Fabre, outside the submitted work. C.G. reports receiving grants and personal fees from Roche; personal fees from Sun Pharma, during the conduct of the study; personal fees from Amgen, MSD, Philogen and Sanofi and grants and personal fees from BMS , Novartis and Neracare, outside the submitted work. R.K. reports receiving personal fees and clinical trial grants from Roche related to aspects of the submitted work, personal fees from Amgen, BMS, Novartis, Regeneron and Actelis, as well as clinical trial grants to his institution from Amgen , BMS , Novartis , Abbvie , Almirall , Biogen , MSD and Pfizer, outside the submitted work. L.B. reports receiving personal fees from Amgen, BMS, Novartis, Merck, Roche, Eisai, Astra Zeneca and Pfizer, outside the submitted work. N.B.-S. reports receiving grants and personal fees from Roche ; personal fees from Sun Pharma; non-financial support and other fees from Pelle pharm, during the conduct of the study, and personal fees from Pierre Fabre and Laboratoire Léo, outside the submitted work. V.B. reports giving a few lectures on cutaneous side-effects of targeted therapy and immunotherapy in stage III and IV melanoma for Novartis and MSD.V.d.M. reports receiving fees from Sanofi, Merck and Abbvie and reports receiving payment from BMS to the Hopital Erasme where she was an employee. She also reports receiving research grant from Abbvie and Janssen . R.D. reports having intermittent, project focused consulting and/or advisory relationships with Novartis, Merck Sharp & Dhome (MSD), Bristol-Myers Squibb (BMS), Roche, Amgen, Takeda, Pierre Fabre, Sun Pharma and Sanofi, outside the submitted work. C.H. reports receiving other fees from Pellepharm, during the conduct of the study; personal fees from Sanofi; non-financial support from MEDA; other fees from Novartis and Galderma and grants from Almirall , CERIES/Chanel and Leo, outside the submitted work. A.H. reports receiving grants and personal fees from Amgen , BMS , MerckSerono , MSD/Merck , Novartis Pharma Philogen , Pierre Fabre , Provectus , Regeneron , Roche and Sanofi-Genzyme and personal fees from OncoSec and Sun Pharma, outside the submitted work. C.H. reports receiving personal fees from Amgen, BMS, MSD, Novartis, Sanofi, Incyte, Pierre Fabre and Roche, outside the submitted work. M.H. reports receiving non-financial support from Cynosure Hologic and Perfaction Technologies; grants from Leo Pharma , Procter and Gamble and Sebacia and grants and non-financial support from Lutronic Novoxel, outside the submitted work. J.M. reports receiving grants and personal fees from Roche; personal fees from Sun Pharma, during the conduct of the study; personal fees and grants from Amgen , Almirall , BMS and Novartis and personal fees from MSD, outside the submitted work. M.R.M. reports receiving personal fees from Amgen and BiolineRx; grants and personal fees from Roche and GSK ; grants from Astrazeneca; personal fees and other fees from Novartis, Eisai, Array Biopharma,Rigontec and BMS; other fees from Millenium, Pfizer, Regeneron, TCBiopharma, Replimune and Vertex and personal fees, non-financial support and other fees from Immunocore and Merck, outside the submitted work. C.A.M. reports receiving personal fees from Biofrontera and Galderma, outside the submitted work, and reports serving as a board member of Euro-PDT and a national PI for a study sponsored by Biofrontera. E.N. reports receiving personal fees from Novartis, outside the submitted work. A.J.S. reports receiving personal fees and/or research support from Novartis, Roche, BMS, Merck, Abbvie, Pfizer, Sanofi, Regeneron and LEOPharma, outside the submitted work. R.-M.S. reports receiving grants, personal fees and non-financial support from Galderma International and Leo Pharma; grants and non-financial support from Biofrontera , during the conduct of the study; grants and personal fees from Almirall and Novartis; grants from Dr. Wolff-Group , Photonamic, Eli Lilly and Galapagos and personal fees and non-financial support from Janssen, outside the submitted work. L.T. reports no conflict of interest. In addition, L.T reports having a pending patent for TIMER applicator. M.T. reports receiving personal fees from Genesis Pharma, Leo Pharma, Janssen Pharma and Novartis, outside the submitted work. I.Z. reports receiving grants and personal fees from Roche Oncology ; personal fees from Mylan, during the conduct of the study; personal fees from Sanofi Regeneron; grants from Abbvie and personal fees from MSD, Novartis and Meda Pharma, outside the submitted work. A.E. reports receiving personal fees, all outside the submitted work, from BMS, Ellipses, GSK, HalioDX, Incyte, IO Biotech, ISA pharmaceuticals, MedImmune, Merck-Serono, MSD, Novartis, Pfizer, Polynoma, Sellas and Sanofi, as well as equity in RiverDiagnostics, SkylineDx and Theranovir. J.J.G. reports receiving personal fees from MSD, BMS, Roche, Novartis, Amgen, Pierre Fabre Sanofi, Merck Pfizer and Sunpharma, outside the submitted work.

PY - 2020/11

Y1 - 2020/11

UR - https://www.scopus.com/pages/publications/85092231844

U2 - 10.1016/j.ejca.2020.08.006

DO - 10.1016/j.ejca.2020.08.006

M3 - Letter

C2 - 32978037

AN - SCOPUS:85092231844

SN - 0959-8049

VL - 140

SP - 154

EP - 157

JO - European Journal of Cancer

JF - European Journal of Cancer

ER -